Conditioning plan for kids with AML before stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 3 trial studies the best “conditioning” chemotherapy plan before an allogeneic stem cell transplant for children with AML. It may help improve outcomes by testing an approach for kids who are ready for transplant after relapse or specific high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or younger when AML was first diagnosed (and 21 or younger at transplant).
- You must have acute myeloid leukemia (AML) and your doctors must recommend a stem cell transplant with donated cells (not your own cells).
- The transplant must be done at a hospital that is participating in this study.
- You must not have certain other diseases (like MDS or JMML) instead of AML.
- You must be healthy enough for chemotherapy (a poor activity score and major organ problems can disqualify you).
- You must agree to the study and (if you can become pregnant) use reliable birth control and have a negative pregnancy test before treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This trial tests a gentler chemotherapy regimen before a stem cell transplant from a partially matched family donor for patients with acute myeloid leukemia (AML) who are older or have health conditions that make standard transplants risky. The goal is to help patients achieve long-term remission with fewer serious side effects.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
This trial tests a new combination of three chemotherapy drugs (clofarabine, busulfan, and melphalan) given before a stem cell transplant to treat acute myeloid leukemia (AML) in patients who have responded well to initial treatment. The goal is to improve how well the transplant works and how long patients survive.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
This trial tests a risk-adapted conditioning regimen (chemotherapy and/or radiation given before transplant) for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a donor. The goal is to tailor the conditioning strength to each patient’s risk, which may help improve outcomes and reduce side effects.
Hear when a new Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.